Seattle Genetics

In it to make a difference in patients’ lives

At Seagen, all kinds of people—researchers, advocates, analysts, sports fans, art lovers, and cancer survivors—collaborate to make a meaningful impact in cancer care. We're a company and a community where your drive can make a difference.

Who we are

Seagen is a global biotechnology company that develops and commercializes transformative cancer therapies. We’re driven by a singular mission—to make a difference for people impacted by cancer.

As an industry leader in antibody–drug conjugate (ADC) technology, we pioneered the science of harnessing antibodies to deliver cell-killing agents directly to cancer cells. This technology is the foundation of two of our approved medicines—ADCETRIS® (brentuximab vedotin) and PADCEV® (enfortumab vedotin-ejfv).

Today, our research efforts are focused on advancing a pipeline of novel targeted therapies, including TUKYSA® (tucatinib), recently approved for certain metastatic HER2+ breast cancers. We’re also leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents.

Our vision
Improving the lives of people with cancer through innovative targeted therapies

Our mission
To discover, develop, and commercialize transformative cancer medicines to make a meaningful difference in people’s lives

Our Values